How large is the U.S. opportunity for Concord's new product?

The U.S. market for Tofacitinib tablets is estimated at $500 million annually. That is approximately ₹4,000 crore, which is nearly four times Concord's entire FY26 revenue of ₹1,054 crore.

What does Tofacitinib treat?

It is a generic version of a drug used for several autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

Why is this approval important for Concord now?

The company has faced recent revenue headwinds. This approval gives it direct entry into a large U.S. market and is part of its strategy to grow its American generics business.

Pharmaceuticals · Mid cap

Concord Biotech lands USFDA okay for Tofacitinib, a $500M U.S. opportunity

The approval opens a market nearly four times the size of Concord's annual revenue.

— 5 earlier stories on Concord Biotech Ltd. →

CONCORDBIO By Tipsheet Editorial 10 Jun 2026 · 10:10 AM IST Verify on BSE · NSE

Mkt cap₹13,852 cr

P/E53.09×

ROE20.50%

Debt / eq.0.00

Div yld0.59%

$500M Estimated annual U.S. market for Tofacitinib tablets

What's new

USFDA approved Concord's generic Tofacitinib tablets in 5 mg and 10 mg strengths.
Tofacitinib treats autoimmune conditions including rheumatoid arthritis and ulcerative colitis.
The U.S. market for the drug is estimated at $500 million annually.

Why this matters

A $500 million U.S. opportunity is nearly four times Concord's FY26 revenue of ₹1,054 crore. Even a modest market share would be material for a company navigating a revenue decline.

What we're watching

Concord's U.S. launch timing and first prescription orders.
Competitive landscape for other generic Tofacitinib entrants.
Whether the approval translates into revenue growth in coming quarters.

The full read

Concord Biotech got the green light from the USFDA for its generic version of Tofacitinib. The drug treats a range of autoimmune conditions and the U.S. market is worth an estimated $500 million a year. That figure is the story. It represents a market nearly four times the size of Concord's entire FY26 revenue of ₹1,054 crore. For a mid-cap Indian generics firm that has been struggling with a revenue decline, landing an approval for a drug this large is a clear step forward. The immediate challenge shifts from regulatory risk to commercial execution. Can Concord win share in a competitive generics market? The size of the prize makes that the only question that matters.

Questions answered

How large is the U.S. opportunity for Concord's new product?: The U.S. market for Tofacitinib tablets is estimated at $500 million annually. That is approximately ₹4,000 crore, which is nearly four times Concord's entire FY26 revenue of ₹1,054 crore.
What does Tofacitinib treat?: It is a generic version of a drug used for several autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Why is this approval important for Concord now?: The company has faced recent revenue headwinds. This approval gives it direct entry into a large U.S. market and is part of its strategy to grow its American generics business.

Mentioned: USFDA · Tofacitinib tablets · $500 million U.S. market

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on CONCORDBIO →

10 Jun 2026 · 10:10 AM IST Concord Biotech lands USFDA okay for Tofacitinib, a $500M U.S. opportunity
5d ago Concord Biotech expects growth to return in FY27 after profit dropped 30%
8d ago Concord Biotech wins USFDA nod for generic transplant drug
12d ago Concord Biotech's profit falls 30% on a 12% revenue slide
12d ago Concord Biotech profit drops 30% on 11% revenue fall